Elevation Point Wealth Partners LLC Acquires Shares of 18,295 Edwards Lifesciences Corporation $EW

Elevation Point Wealth Partners LLC bought a new position in Edwards Lifesciences Corporation (NYSE:EW) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 18,295 shares of the medical research company’s stock, valued at approximately $1,655,000.

A number of other large investors also recently bought and sold shares of the stock. BlackRock Inc. purchased a new position in shares of Edwards Lifesciences during the 2nd quarter valued at approximately $5,318,092,000. Bank of New York Mellon Corp acquired a new position in shares of Edwards Lifesciences in the second quarter worth about $1,274,082,000. Norges Bank acquired a new stake in shares of Edwards Lifesciences during the 4th quarter valued at about $803,686,000. Deutsche Bank AG purchased a new position in shares of Edwards Lifesciences in the 2nd quarter valued at about $516,552,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Edwards Lifesciences by 278.3% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock worth $434,318,000 after purchasing an additional 4,108,270 shares in the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, VP Daniel J. Lippis sold 619 shares of the stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total value of $56,966.57. Following the completion of the sale, the vice president owned 40,034 shares of the company’s stock, valued at $3,684,329.02. This represents a 1.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the sale, the senior vice president directly owned 15,334 shares in the company, valued at approximately $1,319,950.72. The trade was a 3.57% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 25,570 shares of company stock valued at $2,219,390. 0.31% of the stock is currently owned by insiders.

Edwards Lifesciences Stock Up 0.1%

Shares of NYSE EW opened at $89.89 on Monday. The stock has a market cap of $51.76 billion, a PE ratio of 51.66, a P/E/G ratio of 2.25 and a beta of 0.85. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 12-month low of $72.30 and a 12-month high of $96.29. The company has a 50-day moving average of $89.21 and a 200 day moving average of $84.68.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.04. The business had revenue of $1.74 billion for the quarter, compared to analysts’ expectations of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The business’s revenue for the quarter was up 13.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, sell-side analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on EW. Barclays reissued an “overweight” rating and issued a $110.00 price target (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. Leerink Partners raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and increased their target price for the company from $87.00 to $101.00 in a report on Friday, July 24th. Evercore restated an “outperform” rating and issued a $100.00 target price on shares of Edwards Lifesciences in a research report on Monday, July 6th. Royal Bank Of Canada lifted their price target on Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Finally, Piper Sandler reiterated an “overweight” rating and set a $101.00 price target (up from $100.00) on shares of Edwards Lifesciences in a research report on Friday, July 24th. Seventeen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $100.27.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.